|
 |
Shop
Buscopan Injectable Solution
N-butylscopolammonium bromide, an antispasmodic and anticholinergic for IV use in horses only.Add this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your
veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she
will need to sign and return before we can ship you this product.
Indications:
Buscopan is indicated for the control of abdominal pain colic associated with spasmodic colic, flatulent colic, and simple impactions in horses.
Dosage and Administration:
Administer a single injection of 0.3 mg/kg body weight 0.14 mg/lb, slowly IV. This is equivalent to 30 mg N-butylscopolammonium bromide per 100 kg 220 pounds body weight or 1.5 mL of Buscopan Injectable Solution per 100 kg 220 pounds body weight.
Dosing Table Dosage 0.68 mL/100 lbs.
Body Weight Dose Body Weight Dose Body Weight Dose
[nearest 100 lbs] [
mL] [nearest 100 lbs] [
mL] [nearest 100 lbs] [mL]
200
1.4
1000
6.8
1800
12.2
300 2.0
1100
7.5 1900
12.9
400
2.7
1200
8.2 2000
13.6
500
3.4 1300
8.8 2100 14.3
600
4.1 1400
9.5
2200
15.0
700
4.8
1500
10.2 2300
15.6
800
5.4
1600
10.9 2400
16.3
900
6.1
1700
11.6
2500
17.0
Contraindications:
Buscopan should not be used in impaction colics associated with ileus, or in horses with glaucoma.
Warnings:
Do not use in horses intended for human consumption. Not for use in humans. Keep out of reach of children. If ingested, contact a physician immediately.
Precautions:
Buscopan is not recommended for use in nursing foals or in pregnant or lactating mares, as safety has not been established. The effects of Buscopan may be potentiated by the concomitant use of other anticholinergic drugs. Studies of concomitant administration of Buscopan with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy. The safety of Buscopan has not been established for intramuscular IM administration. Administration of Buscopan results in heart rate elevation. Heart rate can not be used as a valid indicator of severity of pain for 30 minutes following IV injection.
Adverse Reactions:
Transient tachycardia and decreased borborygmal sounds lasted approximately 30 minutes following administration. Transient pupillary dilation may also be observed.
Manufactured for: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506
Buscopan is a registered trademark of Boehringer Ingelheim Pharma GmbH & Co. KG and used under license.
|
|
|
|
Register Now
Top Sellers
For Your Pet
|
